| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE41148 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6605300 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| USRE42096 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
| US6322819 | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Oct, 2018
(5 years ago) | |
|
US6322819 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE41148 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
USRE42096 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
|
US6605300 (Pediatric) | TAKEDA PHARMS USA | Oral pulsed dose drug delivery system |
Apr, 2019
(5 years ago) | |
Adderall Xr 30 is owned by Takeda Pharms Usa.
Adderall Xr 30 contains Amphetamine Aspartate; Amphetamine Sulfate; Dextroamphetamine Saccharate; Dextroamphetamine Sulfate.
Adderall Xr 30 has a total of 8 drug patents out of which 8 drug patents have expired.
Expired drug patents of Adderall Xr 30 are:
- USRE41148
- US6605300
- USRE42096
- US6322819
- US6322819*PED
- USRE41148*PED
- USRE42096*PED
- US6605300*PED
Adderall Xr 30 was authorised for market use on 11 October, 2001.
Adderall Xr 30 is available in capsule, extended release;oral dosage forms.
The generics of Adderall Xr 30 are possible to be released after 21 April, 2019.
Market Authorisation Date: 11 October, 2001
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ADDERALL XR 30 family patents
